The United European Gastroenterology (UEG) Week Virtual 2021 illuminated a wide range of new insights and recommendations for…

Communication between the flexor hallucis longus (FHL) tendon sheath and the ankle joint is well-recognised and is reportedly present…

CHRONIC kidney disease (CKD) affects approximately 700 million individuals worldwide. Many patients with CKD require haemodialysis, and more than two-thirds of these patients have CKD-associated pruritus (CKD-aP). CKD-aP can be bothersome for many patients and drastically affect quality of life, from causing sleep issues to mental health problems. Almost 40% of dialysis patients are at least ‘moderately’ bothered and 19% of patients are at least very much bothered by pruritus.

Chronic kidney disease-associated pruritus (CKD-aP) occurs in over two-thirds of patients undergoing haemodialysis. The aetiology of CKD-aP may be multifactorial, involving immune system and opioid dysregulation, peripheral neuropathy, and toxin deposition. CKD-aP can be extremely bothersome for some patients, affecting health-related quality of life and sleep, as well as increasing the likelihood of hospitalisation, infections, and death.

‘Emerging Treatment Strategies for Motor Fluctuation Management: Therapeutic Options for Newly Detected Motor Fluctuations’ reviews…

At the 7th Congress of the European Academy of Neurology (EAN), held virtually in June 2021, real-world data on the efficacy and safety of…

In recent years, there has been an increasing appreciation of the role that patient characteristics such as age, gender…

In this interview, two experts in the field of acute myeloid leukaemia (AML), Jean-Baptiste Micol, University of Paris-Saclay, France, and Thomas Cluzeau, University Hospital of Nice, France, share their views and debate the current landscape of real-world data in AML research and treatment.

There is a paucity of evidence regarding optimal management of Pasteurella spp. endocarditis. The authors report the first case…